Medicine
Multidrug-Resistant Tuberculosis Treatment Regimens and Monitoring
Quick fact
Scientists have known for decades that multidrug-resistant tuberculosis requires a combination of second-line drugs, but it was only in 2019 that a new regimen, the 6-month bedaquiline/pretomanid/linezolid/moxifloxacin (BPaL) regimen, was shown to be as effective as longer therapies, curing about 90% of patients.
Why this is interesting
Imagine an infection that no longer responds to the strongest antibiotics we have—yet it can still be cured. How do doctors design a treatment when the standard fails?
Read the full explanation
Understanding Multidrug-Resistant Tuberculosis Treatment Regimens and Monitoring
Tuberculosis (TB) is normally treated with a six-month course of four first-line drugs, but when the bacterium becomes resistant to the two most powerful ones—isoniazid and rifampicin—the disease is called multidrug-resistant TB (MDR-TB). The key is that you can't simply replace one drug with another; you need a completely different combination. Think of it like a lock with several tumblers: first-line drugs work on individual components, but when resistance develops, those components change. So doctors use 'second-line' drugs—like bedaquiline, linezolid, and fluoroquinolones—that attack different parts of the bacterium. The treatment regimen must be tailored based on a test called drug susceptibility testing, which tells the clinician which drugs the strain is susceptible to. The goal is to use at least three or four active drugs, preferably including a new-generation agent. Because resistance can develop during treatment, the regimen must be carefully balanced and supervised.
A deeper explanation
The core of an MDR-TB regimen is a combination of second-line drugs that work together to shut down the bacterium's ability to survive and reproduce. The new key player, bedaquiline, targets an enzyme called ATP synthase, which is essential for the bacterium's energy production. Linezolid works by blocking protein synthesis, another critical pathway. By hitting multiple targets at once, the combination makes it very unlikely that the bacterium will mutate to become resistant to all of them. But the drugs are not without toxicity—linezolid can cause bone marrow suppression, and others can cause hearing loss or kidney damage—so monitoring is crucial. This monitoring includes regular sputum culture tests to check whether the bacteria are dying, as well as blood tests and hearing tests to catch side effects early. The treatment lasts at least six months after culture conversion, meaning after the patient's sputum stops showing bacteria. The entire process aims to halt transmission, prevent further resistance, and cure the patient without creating new resistant strains.